STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Life365 has appointed healthcare veteran Jay Roberts as Chief Development Officer to drive strategic growth and partnerships. Roberts, who previously served as an executive advisor to Life365, brings over 30 years of healthcare leadership experience to the role. In his new position, he will focus on securing funding, building strategic partnerships, and fostering stakeholder relationships to accelerate market expansion.

Roberts currently serves as a partner with Ventac Partners and as a venture partner for DigiLife Fund II. His extensive experience includes CEO, COO, and CFO positions at Nasdaq-traded companies, involvement in over 50 M&A and financing transactions, and board positions at various healthcare companies including Cingulate (CING). He previously served as president and CEO of Vyant Bio and held leadership roles at Cancer Genetics and VirMedica.

Loading...
Loading translation...

Positive

  • Appointment of highly experienced executive with 30+ years in healthcare leadership
  • Roberts brings extensive M&A experience with involvement in over 50 transactions
  • Strong network and connections through multiple board positions and venture partnerships
  • Previous familiarity with company as executive advisor indicates smooth transition

Negative

  • None.

News Market Reaction 1 Alert

+0.27% News Effect

On the day this news was published, CING gained 0.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships

SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer.

Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations, payers, and government entities.

In his new position, Roberts will spearhead the company's strategic growth initiatives, including securing funding, building strategic partnerships, and fostering relationships with key stakeholders to accelerate Life365's market expansion and long-term success.

"We've already benefited tremendously from Jay's strategic insights during his time as an advisor," said Life365 Founder and CEO Kent Dicks. "His deep expertise in healthcare finance and innovation, coupled with his passion for advancing medical technology, will be invaluable as we pursue our mission to safely and cost-effectively connect patients to care from the comfort of their homes."

Roberts expressed enthusiasm about his expanded role: "Life365 stands at the forefront of healthcare innovation, leveraging advanced technologies like AI to extract actionable insights from patient-generated health data. These insights enable more proactive, preventive care models that can transform healthcare delivery. I'm excited to collaborate with Kent and our investors as Life365 revolutionizes remote patient monitoring to personalize care, improve outcomes, and enhance patient engagement across the healthcare ecosystem."

Extensive Healthcare Leadership Experience

Beyond his role at Life365, Roberts serves as a partner with Ventac Partners, a global catalyst in life sciences that creates breakthrough companies, bringing scientific innovation to patients worldwide. He is also a venture partner for DigiLife Fund II, where he leads fundraising, due diligence, and investment decisions alongside DigiLife team members and syndicate investment funds.

Roberts' governance expertise extends to several prominent roles, including membership on the Board of Trustees of U.S. Pharmacopeia and service on the boards of directors for multiple healthcare companies, including Cingulate (Nasdaq: CING), Caidya Research, Veriskin, NaviPoint Health, and Vyant Bio.

Until February 2023, Roberts served as president and CEO of Vyant Bio, an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Throughout his distinguished career, Roberts has held chief executive officer, chief operating officer (COO), and chief financial officer (CFO) positions for Nasdaq publicly traded companies and venture and private equity-backed healthcare technology organizations. His experience spans diagnostics, software solutions, and manufacturing companies, with involvement in more than 50 M&A and debt and equity transactions.

Roberts previously served as CEO and COO of Cancer Genetics. Prior to that, he was CFO for VirMedica, an innovative technology solutions company.

A current member of the Alliance of CEOs, Roberts is recognized as a thought leader and expert panelist for numerous programs and publications on topics, including "conscious capitalism," leadership and mentoring, corporate finance, mergers and acquisitions, capital formation, and healthcare innovation. He holds an MBA from the University of Maine.

About Life365

Life365 is a leading developer of virtual care technology solutions that enable healthcare delivery at home. The Life365 platform addresses key care delivery challenges by providing scalable solution integration and logistics to enterprise healthcare organizations, enabling patient connectivity, engagement, and improved outcomes for diverse patient populations.

The platform serves as a single integration point that enables providers, payers, and other stakeholders to implement a proactive, virtual-first care approach to remotely engage and monitor patients with various conditions and needs, including chronic disease management, post-discharge care, and population health management.

Led by an experienced, industry-recognized team, Life365 is a major patent holder of wearables, sensors, and patches driven by machine learning/AI, driving the next generation of scalable remote patient monitoring. Life365 serves as a strategic partner of Microsoft Cloud for Healthcare and the Veterans Administration, supporting the largest population of veterans in the world.

For more information, visit www.life365.health.

Media Contact:
Kendall Paulsen | Life365
media@life365.health
888-818-2322 x705

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/life365-appoints-healthcare-veteran-jay-roberts-as-chief-development-officer-302464588.html

SOURCE Life365

FAQ

Who is Jay Roberts and what is his new role at Life365?

Jay Roberts is a healthcare executive with over 30 years of experience who has been appointed as Chief Development Officer at Life365. He will lead strategic growth initiatives, secure funding, and build partnerships.

What is Jay Roberts' previous experience in healthcare leadership?

Roberts has served as CEO, COO, and CFO for Nasdaq-traded companies, was president and CEO of Vyant Bio, and has been involved in over 50 M&A and financing transactions. He currently partners with Ventac Partners and DigiLife Fund II.

What boards does Jay Roberts currently serve on?

Roberts serves on the Board of Trustees of U.S. Pharmacopeia and the boards of directors for several healthcare companies including Cingulate (CING), Caidya Research, Veriskin, NaviPoint Health, and Vyant Bio.

What will be Jay Roberts' main responsibilities at Life365?

As Chief Development Officer, Roberts will lead strategic growth initiatives, secure funding, build strategic partnerships, and foster relationships with key stakeholders to accelerate Life365's market expansion.
Cingulate Inc

NASDAQ:CING

CING Rankings

CING Latest News

CING Latest SEC Filings

CING Stock Data

28.24M
6.66M
1.81%
5.27%
4.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY